Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the...

|About: Quest Diagnostics Incorporated (DGX)|By:, SA News Editor

Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the company's Stratify JCV Antibody Elisa testing service. The approval means doctors can now test for the risk of a potentially fatal brain infection caused by Tysabri, a multiple sclerosis treatment sold by Biogen Idec (BIIB) and Elan (ELN).